Most doctors do not feel they know enough about these tests to practice practice.

Recognize While the vast majority of doctors the contribution of genetic tests to improve drug reaction in prescribing and dosing of many widely used drugs, most doctors do not feel they know enough about these tests to practice practice. However, new data from the Medco Research Institute – a research subsidiary of Medco Health Solutions – shows when both physicians and patients informed about decisions regarding testing and the process is made convenient, The new data was of genetic tests increased significantly – an advance safe and effective safer and more effective use of medication. The new data was last weekend. At the annual meeting of the American Society for Human Genetics..

The use of genetic testing in patients on blood thinner warfarin and the breast cancer prevention drug tamoxifen in daily practice in daily practice. But according to the analysis, when a proactive pharmacy-based pharmacogenomic testing program was implemented, the incidence of testing in patients on warfarin was nearly 45 times higher, and was nearly 7 – fold higher in patients treated with tamoxifen compared to the pre – program period. It is quite remarkable that we are so saw a huge jump in the adoption of genetic tests for the Proactive Outreach for physicians and patients to inform them about the availability of the test, said Eric Stanek, Medco senior director of the Personalized Medical research and the study’s lead researcher. This is a very important step in creating a model that can move substantially. Continue reading “Most doctors do not feel they know enough about these tests to practice practice.”